# A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

> **NCT02605083** · PHASE1,PHASE2 · TERMINATED · sponsor: **Effector Therapeutics** · enrollment: 66 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** eFT508

## Key facts

- **NCT ID:** NCT02605083
- **Lead sponsor:** Effector Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-03
- **Primary completion:** 2019-01-11
- **Final completion:** 2019-03-22
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** The study was terminated after determination of the RP2D, prior to opening expansion cohorts)
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605083, "A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02605083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*